T he use of spironolactone increased considerably following publication of the Randomized Aldactone Evaluation Study, which showed that the drug improved morbidity and mortality in carefully selected patients with severe systolic heart failure.1,2 Although spironolactone is generally well tolerated, hyperkalemia is a potentially life-threatening adverse effect of the drug in clinical practice.3-5 Strategies for mitigating the risk of serious hyperkalemia include cautious dosing of spironolactone, close monitoring of electrolyte levels and avoidance of other drugs that cause hyperkalemia.The widely used antibiotic trimethoprim has pharmacologic similarities to the potassium-sparing diuretic amiloride. It reduces urinary potassium excretion by about 40% and can increase the risk of life-threatening hyperkalemia in susceptible individuals, including those taking spironolactone.6,7 In combination with sulfamethoxazole, trimethoprim is most often used for the treatment of urinary tract infections. More than 20 million prescriptions are written for the combination each year in the United States. 8 We have previously shown that the use of trimethoprim-sulfamethoxazole in patients receiving spironolactone increased the risk of hospital admission with hyperkalemia more than 12-fold relative to amoxicillin.9 However, we did not examine whether the drug interaction was associated with an increased risk of sudden cardiac death, a predictable consequence of severe hyperkalemia. 10,11 This is important because sudden death in patients taking spironolactone may erroneously be attributed to intrinsic heart disease.Because treatment with trimethoprimsulfamethoxazole can precipitate life-threatening hyperkalemia in patients receiving spironolactone, we conducted a study to determine whether